Enanta Pharmaceuticals traded at $14.30 this Friday February 27th, decreasing $0.11 or 0.76 percent since the previous trading session. Looking back, over the last four weeks, Enanta Pharmaceuticals lost 13.04 percent. Over the last 12 months, its price rose by 83.80 percent. Looking ahead, we forecast Enanta Pharmaceuticals to be priced at 13.09 by the end of this quarter and at 11.91 in one year, according to Trading Economics global macro models projections and analysts expectations.
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company uses chemistry-driven approach and drug discovery capabilities. The Company is focused on discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). It also conducts research in human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease-2019 (COVID-19). The Company has discovered glecaprevir, a protease inhibitor discovered and developed through its collaboration with AbbVie for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie’s direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET.